In its Q2 2026 conference call, Krystal Biotech, Inc. reported robust financial growth and significant advances in its clinical pipeline. The company achieved $119.2 million in net product revenue, marking a 24% increase, primarily due to the continued rollout of its gene therapy, VYJUVEK. The U.S. market showed strong performance with over 730 reimbursement approvals, surpassing initial goals for the dystrophic epidermolysis bullosa patient pool. While European revenues were flat due to ongoing pricing negotiations in Germany, the company remains optimistic about future growth, especially with planned regulatory submissions for new markets.
On the clinical side, the company is progressing with its pipeline, targeting several key readouts in the second half of 2026, including data from registrational studies for ocular diseases. The CEO underscored the company’s transformative potential over the coming years, transitioning towards a multi-product genetic medicines entity. Overall, Krystal is well-positioned financially with over $1.1 billion in cash, allowing for strategic investments in global expansion and ongoing clinical trials.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.theglobeandmail.com/investing/markets/markets-news/motley/3767540/krystal-biotech-krys-q2-2026-earnings-call-transcript/
